Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 151

1.

Seleno-auranofin (Et3PAuSe-tagl): synthesis, spectroscopic (EXAFS, 197Au Mössbauer, 31P, 1H, 13C, and 77Se NMR, ESI-MS) characterization, biological activity, and rapid serum albumin-induced triethylphosphine oxide generation.

Hill DT, Isab AA, Griswold DE, DiMartino MJ, Matz ED, Figueroa AL, Wawro JE, DeBrosse C, Reiff WM, Elder RC, Jones B, Webb JW, Shaw CF.

Inorg Chem. 2010 Sep 6;49(17):7663-75. doi: 10.1021/ic902335z.

PMID:
20704360
2.

Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice.

Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, Egenolf DD, Bugelski PJ, Murray LA, Marsters PA, Bunting RA, Flavell RA, Alexopoulou L, San Mateo LR, Griswold DE, Sarisky RT, Mbow ML, Das AM.

Respir Res. 2009 Jun 1;10:43. doi: 10.1186/1465-9921-10-43.

3.

Identification of interleukin-13 related biomarkers using peripheral blood mononuclear cells.

Syed F, Huang CC, Li K, Liu V, Shang T, Amegadzie BY, Griswold DE, Song XY, Li L.

Biomarkers. 2007 Jul-Aug;12(4):414-23.

PMID:
17564846
4.

Dermokine: an extensively differentially spliced gene expressed in epithelial cells.

Naso MF, Liang B, Huang CC, Song XY, Shahied-Arruda L, Belkowski SM, D'Andrea MR, Polkovitch DA, Lawrence DR, Griswold DE, Sweet RW, Amegadzie BY.

J Invest Dermatol. 2007 Jul;127(7):1622-31. Epub 2007 Mar 22.

5.

Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus.

Liang B, Gardner DB, Griswold DE, Bugelski PJ, Song XY.

Immunology. 2006 Nov;119(3):296-305.

6.

Biopharmaceutical therapeutics for asthma remodeling.

Das AM, Griswold DE, Torphy TJ, Li L.

Curr Pharm Des. 2006;12(25):3233-40. Review.

PMID:
17020531
7.

Ex vivo activated OVA specific and non-specific CD4+CD25+ regulatory T cells exhibit comparable suppression to OVA mediated T cell responses.

Li J, Bracht M, Shang X, Radewonuk J, Emmell E, Griswold DE, Li L.

Cell Immunol. 2006 Jun;241(2):75-84. Epub 2006 Sep 27.

PMID:
17010326
8.

IgE isotype switch and IgE production are enhanced in IL-21-deficient but not IFN-gamma-deficient mice in a Th2-biased response.

Shang XZ, Ma KY, Radewonuk J, Li J, Song XY, Griswold DE, Emmell E, Li L.

Cell Immunol. 2006 Jun;241(2):66-74. Epub 2006 Sep 18.

PMID:
16979605
9.

Role of chemokines in severe asthma.

Murray LA, Syed F, Li L, Griswold DE, Das AM.

Curr Drug Targets. 2006 May;7(5):579-88. Review.

PMID:
16719768
10.

Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.

Li J, Davis J, Bracht M, Carton J, Armstrong J, Gao W, Scallon B, Fung R, Emmell E, Zimmerman M, Griswold DE, Li L.

Int Immunopharmacol. 2006 Jun;6(6):880-91. Epub 2006 Jan 27.

PMID:
16644473
11.

IL-4 and IL-13 form a negative feedback circuit with surfactant protein-D in the allergic airway response.

Haczku A, Cao Y, Vass G, Kierstein S, Nath P, Atochina-Vasserman EN, Scanlon ST, Li L, Griswold DE, Chung KF, Poulain FR, Hawgood S, Beers MF, Crouch EC.

J Immunol. 2006 Mar 15;176(6):3557-65.

12.

Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice.

Yang G, Li L, Volk A, Emmell E, Petley T, Giles-Komar J, Rafferty P, Lakshminarayanan M, Griswold DE, Bugelski PJ, Das AM.

J Pharmacol Exp Ther. 2005 Apr;313(1):8-15. Epub 2005 Jan 11.

PMID:
15644434
14.

Anti-IL-13 monoclonal antibody inhibits airway hyperresponsiveness, inflammation and airway remodeling.

Yang G, Volk A, Petley T, Emmell E, Giles-Komar J, Shang X, Li J, Das AM, Shealy D, Griswold DE, Li L.

Cytokine. 2004 Dec 21;28(6):224-32.

PMID:
15566951
15.

Regulation of antigen-specific versus by-stander IgE production after antigen sensitization.

Shang XZ, Armstrong J, Yang GY, Volk A, Li J, Griswold DE, Emmell E, Li L.

Cell Immunol. 2004 Jun;229(2):106-16.

PMID:
15474525
16.

Induction of dendritic cell maturation by IL-18.

Li J, Mbow ML, Sun L, Li L, Yang G, Griswold DE, Schantz A, Shealy DJ, Goletz TJ, Wan J, Peritt D.

Cell Immunol. 2004 Feb;227(2):103-8.

PMID:
15135292
17.

Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.

Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, Griswold DE, Martin L, Lee JM, White JR, Sarau HM.

J Med Chem. 2004 Mar 11;47(6):1319-21.

PMID:
14998320
18.

Coming of age: anti-cytokine therapies.

Song XY, Torphy TJ, Griswold DE, Shealy D.

Mol Interv. 2002 Feb;2(1):36-46. Review.

PMID:
14993360
19.

PGE2 and IL-6 production by fibroblasts in response to titanium wear debris particles is mediated through a Cox-2 dependent pathway.

Bukata SV, Gelinas J, Wei X, Rosier RN, Puzas JE, Zhang X, Schwarz EM, Song XY, Griswold DE, O'Keefe RJ.

J Orthop Res. 2004 Jan;22(1):6-12.

20.

What's in the pipeline? Prospects for monoclonal antibodies (mAbs) as therapies for lung diseases.

Li L, Das AM, Torphy TJ, Griswold DE.

Pulm Pharmacol Ther. 2002;15(5):409-16. Review.

PMID:
12406662
21.

Anti-TNF-alpha antibody allows healing of joint damage in polyarthritic transgenic mice.

Shealy DJ, Wooley PH, Emmell E, Volk A, Rosenberg A, Treacy G, Wagner CL, Mayton L, Griswold DE, Song XY.

Arthritis Res. 2002;4(5):R7. Epub 2002 Jun 28.

22.

Nonpeptide tachykinin receptor antagonists. III. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper-reactivity in guinea pigs.

Hay DW, Giardina GA, Griswold DE, Underwood DC, Kotzer CJ, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Martin LD, Kilian D, Legos JJ, Barone FC, Luttmann MA, Grugni M, Raveglia LF, Sarau HM.

J Pharmacol Exp Ther. 2002 Jan;300(1):314-23.

PMID:
11752131
23.

Monoclonal antibodies as a strategy for pulmonary diseases.

Torphy TJ, Li L, Griswold DE.

Curr Opin Pharmacol. 2001 Jun;1(3):265-71. Review.

PMID:
11712750
24.

Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.

Adams JL, Boehm JC, Gallagher TF, Kassis S, Webb EF, Hall R, Sorenson M, Garigipati R, Griswold DE, Lee JC.

Bioorg Med Chem Lett. 2001 Nov 5;11(21):2867-70.

PMID:
11597418
25.

Targeted disruption of the endothelin-B-receptor gene attenuates inflammatory nociception and cutaneous inflammation in mice.

Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH.

J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S78-81.

PMID:
11078342
26.

SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung.

Underwood DC, Osborn RR, Bochnowicz S, Webb EF, Rieman DJ, Lee JC, Romanic AM, Adams JL, Hay DW, Griswold DE.

Am J Physiol Lung Cell Mol Physiol. 2000 Nov;279(5):L895-902.

27.

Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.

Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 2000 Oct;295(1):373-81.

PMID:
10992004
28.

Inhibition of p38 MAP kinase as a therapeutic strategy.

Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL.

Immunopharmacology. 2000 May;47(2-3):185-201. Review.

PMID:
10878289
29.

Human granulocyte CD11b expression as a pharmacodynamic biomarker of inflammation.

Davis HM, Carpenter DC, Stahl JM, Zhang W, Hynicka WP, Griswold DE.

J Immunol Methods. 2000 Jun 23;240(1-2):125-32.

PMID:
10854607
30.

Identification and initial characterization of four novel members of the interleukin-1 family.

Kumar S, McDonnell PC, Lehr R, Tierney L, Tzimas MN, Griswold DE, Capper EA, Tal-Singer R, Wells GI, Doyle ML, Young PR.

J Biol Chem. 2000 Apr 7;275(14):10308-14.

31.

SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.

Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DW, Griswold DE.

J Pharmacol Exp Ther. 2000 Apr;293(1):281-8.

PMID:
10734180
32.
33.

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, Boehm JC, Adams JL, Lee JC.

Arthritis Rheum. 2000 Jan;43(1):175-83.

34.

Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis.

Badger AM, Blake SM, Dodds RA, Griswold DE, Swift BA, Rieman DJ, Stroup GB, Hoffman SJ, Gowen M.

J Pharmacol Exp Ther. 1999 Dec;291(3):1380-6.

PMID:
10565864
35.

Endothelin B receptor modulates inflammatory pain and cutaneous inflammation.

Griswold DE, Douglas SA, Martin LD, Davis TG, Davis L, Ao Z, Luttmann MA, Pullen M, Nambi P, Hay DW, Ohlstein EH.

Mol Pharmacol. 1999 Oct;56(4):807-12.

PMID:
10496965
36.

In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity.

Sarau HM, Foley JJ, Schmidt DB, Martin LD, Webb EF, Tzimas MN, Breton JJ, Chabot-Fletcher M, Underwood DC, Hay DW, Kingsbury WD, Chambers PA, Pendrak I, Jakas DR, Sathe GM, Van Horn S, Daines RA, Griswold DE.

Prostaglandins Leukot Essent Fatty Acids. 1999 Jul;61(1):55-64.

PMID:
10477044
37.

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH.

Pulm Pharmacol Ther. 1999;12(2):131-5. Review. No abstract available.

PMID:
10373396
38.

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

Adams JL, Boehm JC, Kassis S, Gorycki PD, Webb EF, Hall R, Sorenson M, Lee JC, Ayrton A, Griswold DE, Gallagher TF.

Bioorg Med Chem Lett. 1998 Nov 17;8(22):3111-6.

PMID:
9873686
39.

SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.

Griswold DE, Webb EF, Badger AM, Gorycki PD, Levandoski PA, Barnette MA, Grous M, Christensen S, Torphy TJ.

J Pharmacol Exp Ther. 1998 Nov;287(2):705-11.

PMID:
9808700
40.
41.

Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration.

White JR, Lee JM, Young PR, Hertzberg RP, Jurewicz AJ, Chaikin MA, Widdowson K, Foley JJ, Martin LD, Griswold DE, Sarau HM.

J Biol Chem. 1998 Apr 24;273(17):10095-8.

42.

Evaluation of the cutaneous anti-inflammatory activity of azaspiranes.

Griswold DE, Martin LD, Badger AM, Breton J, Chabot-Fletcher M.

Inflamm Res. 1998 Feb;47(2):56-61.

PMID:
9535542
43.

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf WE Jr, Barnette MS, Underwood DC, Griswold DE, Cieslinski LB, Burman M, Bochnowicz S, Osborn RR, Manning CD, Grous M, Hillegas LM, Bartus JO, Ryan MD, Eggleston DS, Haltiwanger RC, Torphy TJ.

J Med Chem. 1998 Mar 12;41(6):821-35.

PMID:
9526558
44.

Beta-lactams SB 212047 and SB 216754 are irreversible, time-dependent inhibitors of coenzyme A-independent transacylase.

Winkler JD, Sung CM, Chabot-Flecher M, Griswold DE, Marshall LA, Chilton FH, Bondinell W, Mayer RJ.

Mol Pharmacol. 1998 Feb;53(2):322-9.

PMID:
9463491
45.

Pharmacological effects of SB 220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models.

Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD.

J Pharmacol Exp Ther. 1998 Feb;284(2):687-92.

PMID:
9454815
46.

In vitro and in vivo characterization of NK3 receptors in the rabbit eye by use of selective non-peptide NK3 receptor antagonists.

Medhurst AD, Hay DW, Parsons AA, Martin LD, Griswold DE.

Br J Pharmacol. 1997 Oct;122(3):469-76.

47.

Re-classification of NSAIDs.

Griswold DE, Ruffolo RR, Poste G, Torphy TJ.

Trends Pharmacol Sci. 1997 Sep;18(9):311-2. No abstract available.

PMID:
9345847
48.

Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli.

Kumar S, Tzimas MN, Griswold DE, Young PR.

Biochem Biophys Res Commun. 1997 Jun 27;235(3):474-8.

PMID:
9207179
49.

Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.

Sarau HM, Griswold DE, Potts W, Foley JJ, Schmidt DB, Webb EF, Martin LD, Brawner ME, Elshourbagy NA, Medhurst AD, Giardina GA, Hay DW.

J Pharmacol Exp Ther. 1997 Jun;281(3):1303-11.

PMID:
9190866
50.

Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterizing N-hydroxy-N-(2,3-dihydro-6-(phenylmethoxy)-3-benzofuranyl)urea.

Adams JL, Garigipati RS, Sorenson M, Schmidt SJ, Brian WR, Newton JF, Tyrrell KA, Garver E, Yodis LA, Chabot-Fletcher M, Tzimas M, Webb EF, Breton JJ, Griswold DE.

J Med Chem. 1996 Dec 20;39(26):5035-46.

PMID:
8978834

Supplemental Content

Loading ...
Support Center